Fulgent Genetics (FLGT) Income from Continuing Operations (2015 - 2026)

Fulgent Genetics has disclosed Income from Continuing Operations across 12 years of filings, most recently posting -$29.7 million for Q2 2026.

• In Q2 2026, Income from Continuing Operations fell 54.64% year-over-year to -$29.7 million; the TTM figure through Jun 2026 stood at -$79.2 million (down 52.12% YoY), while the FY2025 annual figure was -$55.3 million, down 26.24% from the prior year.
• Income from Continuing Operations came in at -$29.7 million for Q2 2026 at Fulgent Genetics, down from -$25.3 million in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of $153.6 million in Q1 2022 to a low of -$122.9 million in Q4 2023.
• Average Income from Continuing Operations over 5 years is -$9.8 million, with a median of -$13.7 million recorded in 2023.
• Year-over-year, Income from Continuing Operations tumbled 1102.68% in 2023 and surged 94.95% in 2024.
• Over 5 years, Income from Continuing Operations stood at -$24.1 million in 2022, then tumbled by 410.33% to -$122.9 million in 2023, then surged by 94.95% to -$6.2 million in 2024, then plunged by 179.74% to -$17.4 million in 2025, then slumped by 71.11% to -$29.7 million in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were -$29.7 million in Q2 2026, -$25.3 million in Q1 2026, and -$17.4 million in Q4 2025.